Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral treprostinil Clear all
Terminated Phase 3 Interventional Results available

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Oral treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 10:54 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

NCT04791514
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 21, 2026, 10:54 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 21, 2026, 10:54 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606, Placebo
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Standardized meals
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 21, 2026, 10:54 PM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 21, 2026, 10:54 PM EDT
Recruiting Phase 4 Interventional

Open Label Treprostinil Raynaud's Study

NCT07112183
View directory record Official record
Conditions
Raynaud's Disease, Raynaud Phenomena, Raynauds
Interventions
Oral treprostinil (UT-15C) sustained release tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Active, not recruiting No phase listed Observational

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

NCT03045029
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Recruiting Phase 4 Interventional

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

NCT07759804
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
LIQ861 (treprostinil) inhalation powder
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 21, 2026, 10:54 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

NCT01104870
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 21, 2026, 10:54 PM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 21, 2026, 10:54 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

NCT02318758
View directory record Official record
Conditions
Healthy
Interventions
UT-15C, ethanol
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 21, 2026, 10:54 PM EDT
Withdrawn Phase 2 Interventional

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT02603068
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Remodulin® to Oral Treprostinil Transition

NCT01588405
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C SR
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
15 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

NCT02663895
View directory record Official record
Conditions
Systemic Sclerosis, Calcinosis
Interventions
Oral treprostinil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 21, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

NCT01131845
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Renal Dysfunction
Interventions
UT-15C SR (treprostinil diethanolamine)
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 21, 2026, 10:54 PM EDT